Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $130 to $133.
Guggenheim analyst Michael Schmitz maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $...
Baird analyst Joel Beatty maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $11...
Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $130 price target.
Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $...
